HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 06-12-2007, 05:58 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
??the end of lymph node biopsy and lymphedema approaching???

ABSTRACT: Regional Lymph Node Metastases; a Singular Manifestation of the Process of Clinical Metastases in Cancer: Contemporary Animal Research and Clinical Reports Suggest Unifying Concepts [Annals of Surgery]
Research results from laboratory animals and human clinical reports provide insight into cancer cell disseminations and elaborate the complex metastatic cascade of cells into both regional lymph nodes and other distant organs. Critical appraisal of clinical trials indicates that lymph node metastases are themselves non-lethal, but indicate prognosis, confirming laboratory conclusions. Distant vital organ metastases can be resected with long term survival in highly selective situations, demonstrating metastatic specificity in oligometastatic disease.
Appreciating lymphatic system embryology, anatomy, and physiology is necessary for understanding lymph node metastases. The primary lymphatic system function was to return interstitial fluid to the circulation. Later evolutionary insertion of lymphocyte collections in lymph nodes interrupting lymph flow completed a system of analyzing external antigens to enable adaptive immunologic responses. Human cancers seldom elicit major immunological responses; they are not generally "foreign" enough. Therefore, lymphatic metastases have little meaning in evolutionary terms.
Organ specificity of both lymphatic and distant metastases occurs as metastatic cells lie dormant, but grow selectively only in liver, lung, bone, or lymph nodes. These organ specific metastatic cells have little ability to produce different organ site clinical metastases.
Thus, laboratory findings and clinical correlations emphasize that surgical lymph node removal should be de-emphasized or omitted. More physiological approaches to the highly manipulable multi-step processes of clinical metastases arising from host microenvironments will eventually prevail.
Lani is offline   Reply With Quote
Old 06-12-2007, 10:28 AM   #2
Caroline UK
Senior Member
 
Join Date: Nov 2006
Location: London, England
Posts: 96
Question Not sure I understand...can someone help?

Lani, thanks so much for posting this. Very interesting. I had to read it a few times, but I think I understand most of it now. I wondered, though, if you or anyone else might be able to make something clearer for me:

If this is saying that metastatic disease is organ-specific, and doesn't spread to other organs easily, why does it matter how many lymph nodes are found to contain cancer cells? My understanding is that anything over 4 lymph nodes is considered a higher risk for recurrence later. I had assumed that this was because it meant that the cancer was a particularly fast-growing or aggressive type. Is this saying that it doesn't spread from the lymph nodes? I.e. that for example, breast cancer cells may have metastasised to the liver, or brain, or bones, and may grow there, but won't spread to other organs?


Hope my question makes sense to someone!
__________________
Caroline
Diag. March 10th 2006, aged 46.
Invasive ductal carcinoma, 2cm + multifocal. Stage 2, Grade 3
HER2+++, ER+/PR+
Right mast. May 2006. 6 of 20 nodes positive
FEC x 4, taxotere x 4; port implanted after 6 cycles
Rads x 25
1 year of Herceptin ended Nov 07.
Arimidex 5 years

Considering reconstruction, maybe soon...
Caroline UK is offline   Reply With Quote
Old 06-12-2007, 10:38 AM   #3
tousled1
Senior Member
 
tousled1's Avatar
 
Join Date: Feb 2006
Location: Acworth, GA
Posts: 2,104
I too had to read the article several times. I had 26 nodes remove 14 of which were positive. I was old tht with having so many positive nodes increased my chances of mets. Does this aticle contradict this?
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
tousled1 is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 09:14 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter